Syed Ali, MD
Dermatology · Northridge
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 27 years
- University of Chicago, Pritzker School of Medicine, 1999
Offices
1 location · Skin and Beauty Center Inc · 34 clinicians in this group
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ali’s office at (818) 886-3884 to ask if they take your plan before you enroll.
State licence records
1 licence
- Texas N9338Physician License · since 2011 · expires 2028-05-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Original Medicare doctor bills
$42,095
Medicare paid this office $42,095 for 184 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 98 | $8,415 | $57 |
| Biopsy of related skin growth, first growth | 62 | $4,657 | $64 |
| Short return visit | 60 | $3,819 | $39 |
| Return visit (30+ min) | 22 | $2,733 | $91 |
| Destruction of precancer skin growth, 1 growth | 54 | $2,566 | $36 |
See all 11 services
| Short return visit (20+ min) | 98 | $8,415 | $57 |
| Biopsy of related skin growth, first growth | 62 | $4,657 | $64 |
| Short return visit | 60 | $3,819 | $39 |
| Return visit (30+ min) | 22 | $2,733 | $91 |
| Destruction of precancer skin growth, 1 growth | 54 | $2,566 | $36 |
| Destruction of skin growth, 1-14 growths | 25 | $2,361 | $74 |
| Destruction of precancer skin growth, 15 or more growths | 13 | $2,217 | $96 |
| New patient visit (30+ min) | 27 | $1,692 | $63 |
| New patient visit (15+ min) | 29 | $1,338 | $46 |
| Destruction of precancer skin growth, 2-14 growths | 33 | $1,123 | $5 |
| Biopsy of related skin growth, each additional growth | 23 | $956 | $37 |
Procedures Medicare counted
| Melanoma (skin cancer) excision | 12 | More than 66% of doctors who do this |
| Removal of nail tissue | 1-10 | None |
| Removal of skin cancer | 1-10 | None |
| Removal of skin lesions | 431 | More than 85% of doctors who do this |
| Removal or shaving of skin growth | 1-10 | None |
| Skin biopsy | 171 | More than 83% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 296 | 241 | 192 | 346 | 269 | 227 |
| Destruction of precancer skin growth, 1 growth | 81 | 65 | 68 | 84 | 72 | 71 |
| Biopsy of related skin growth, first growth | 51 | 33 | 38 | 50 | 48 | 73 |
| Destruction of skin growth, 1-14 growths | 49 | 39 | 23 | 47 | 51 | 32 |
| Destruction of precancer skin growth, 15 or more growths | 25 | – | 27 | 35 | 16 | 23 |
| Biopsy of related skin growth, each additional growth | 20 | – | – | 15 | – | 26 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
184 Original Medicare patients in 2024. Average age 71 · Women 47% · Also on Medicaid 14% · Health risk score 1.11. Above the middle of the specialty; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 73% · Diabetes 35% · Coronary heart disease 28% · Chronic kidney disease 18% · Atrial fibrillation 15% · Heart failure 11% · Depression 11% · Cancer 9% · COPD 9%.
The office billed $88,279, Medicare allowed $59,664 and paid $42,095; for 890 services of 44 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 184 | 890 | 71 | 1.11 | $88,279 | $42,095 |
| 2023 | 185 | 903 | 71 | 1.16 | $81,499 | $39,080 |
| 2022 | 193 | 1,015 | 70 | 1.13 | $91,360 | $47,003 |
| 2021 | 156 | 686 | 71 | 0.82 | $60,021 | $29,927 |
| 2020 | 149 | 756 | 72 | 0.99 | $81,740 | $38,742 |
| 2019 | 206 | 999 | 71 | 0.97 | $102,468 | $49,573 |
| 2018 | 199 | 944 | 71 | 1.31 | $104,470 | $49,812 |
| 2017 | 173 | 758 | 71 | 1.13 | $76,175 | $36,786 |
| 2016 | 116 | 524 | 72 | 1.03 | $56,375 | $27,530 |
| 2015 | 141 | 538 | 73 | 1.05 | $46,571 | $28,143 |
| 2014 | 135 | 572 | 73 | 0.90 | $44,401 | $26,920 |
| 2013 | 143 | 451 | 74 | 0.92 | $41,531 | $25,900 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Short return visit (20+ min) | 96 | $7,629 | $53 |
| Destruction of skin growth, 1-14 growths | 37 | $3,987 | $78 |
| Management of oxygen chamber therapy | 12 | $3,633 | $81 |
| Short return visit | 62 | $3,168 | $36 |
| Biopsy of related skin growth, first growth | 44 | $2,946 | $61 |
| Destruction of precancer skin growth, 1 growth | 57 | $2,391 | $33 |
| New patient visit (30+ min) | 32 | $1,726 | $54 |
| Destruction of precancer skin growth, 15 or more growths | 12 | $1,710 | $107 |
| New patient visit (15+ min) | 33 | $1,267 | $38 |
| Destruction of precancer skin growth, 2-14 growths | 42 | $1,199 | $4 |
| Return visit (30+ min) | 13 | $1,123 | $80 |
2022: 10 services
| Short return visit (20+ min) | 74 | $6,621 | $59 |
| New patient visit (30+ min) | 54 | $4,120 | $76 |
| Destruction of skin growth, 1-14 growths | 41 | $3,706 | $79 |
| Destruction of precancer skin growth, 15 or more growths | 26 | $3,706 | $106 |
| Short return visit | 67 | $3,481 | $36 |
| Biopsy of related skin growth, first growth | 47 | $3,212 | $64 |
| Destruction of precancer skin growth, 1 growth | 61 | $3,067 | $37 |
| Destruction of precancer skin growth, 2-14 growths | 48 | $1,771 | $5 |
| New patient visit (15+ min) | 34 | $1,558 | $46 |
| Biopsy of related skin growth, each additional growth | 11 | $557 | $37 |
2021: 10 services
| Short return visit (20+ min) | 51 | $4,255 | $60 |
| Short return visit | 63 | $3,000 | $34 |
| Destruction of precancer skin growth, 15 or more growths | 18 | $2,986 | $111 |
| Biopsy of related skin growth, first growth | 36 | $2,624 | $69 |
| Destruction of precancer skin growth, 1 growth | 52 | $2,249 | $33 |
| Destruction of skin growth, 1-14 growths | 19 | $1,897 | $82 |
| New patient visit (30+ min) | 30 | $1,837 | $61 |
| New patient visit (15+ min) | 28 | $1,305 | $47 |
| Return visit (30+ min) | 13 | $1,072 | $71 |
| Destruction of precancer skin growth, 2-14 growths | 36 | $915 | $5 |
2020: 8 services
| Return visit (30+ min) | 56 | $6,530 | $77 |
| Short return visit (20+ min) | 60 | $4,515 | $49 |
| Destruction of skin growth, 1-14 growths | 21 | $2,631 | $67 |
| New patient visit (30+ min) | 36 | $2,604 | $72 |
| Destruction of precancer skin growth, 1 growth | 49 | $2,503 | $39 |
| Biopsy of related skin growth, first growth | 31 | $2,147 | $65 |
| New patient visit (15+ min) | 34 | $1,410 | $41 |
| Destruction of precancer skin growth, 2-14 growths | 39 | $1,069 | $4 |
2019: 10 services
| Return visit (30+ min) | 74 | $6,938 | $70 |
| Short return visit (20+ min) | 82 | $6,314 | $49 |
| Destruction of skin growth, 1-14 growths | 18 | $3,775 | $77 |
| Biopsy of related skin growth, first growth | 42 | $3,414 | $67 |
| Destruction of precancer skin growth, 1 growth | 63 | $3,090 | $38 |
| New patient visit (30+ min) | 46 | $3,035 | $66 |
| Destruction of precancer skin growth, 15 or more growths | 18 | $2,615 | $105 |
| New patient visit (15+ min) | 51 | $2,611 | $51 |
| Destruction of precancer skin growth, 2-14 growths | 44 | $1,202 | $4 |
| Biopsy of related skin growth, each additional growth | 13 | $810 | $40 |
2018: 11 services
| Return visit (30+ min) | 81 | $8,137 | $71 |
| Management of oxygen chamber therapy | 11 | $6,574 | $83 |
| Short return visit (20+ min) | 62 | $4,560 | $47 |
| Biopsy of single growth of skin and/or tissue | 52 | $4,183 | $72 |
| Destruction of precancer skin growth, 15 or more growths | 21 | $3,685 | $102 |
| New patient visit (30+ min) | 50 | $3,540 | $71 |
| Destruction of skin growth, 1-14 growths | 24 | $3,280 | $71 |
| Destruction of precancer skin growth, 1 growth | 58 | $2,823 | $38 |
| New patient visit (15+ min) | 56 | $2,767 | $49 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 13 | $2,434 | $187 |
| Destruction of precancer skin growth, 2-14 growths | 37 | $865 | $4 |
2017: 9 services
| New patient visit (30+ min) | 78 | $5,466 | $70 |
| Short return visit (20+ min) | 55 | $4,193 | $49 |
| Biopsy of single growth of skin and/or tissue | 51 | $3,743 | $72 |
| Return visit (30+ min) | 39 | $3,609 | $77 |
| Destruction of precancer skin growth, 1 growth | 55 | $2,814 | $40 |
| New patient visit (15+ min) | 51 | $2,601 | $51 |
| Destruction of precancer skin growth, 15 or more growths | 17 | $2,402 | $109 |
| Destruction of skin growth, 1-14 growths | 19 | $2,128 | $71 |
| Destruction of precancer skin growth, 2-14 growths | 43 | $1,062 | $4 |
2016: 8 services
| Short return visit (20+ min) | 47 | $3,634 | $52 |
| New patient visit (30+ min) | 53 | $3,617 | $68 |
| Biopsy of single growth of skin and/or tissue | 40 | $3,185 | $72 |
| New patient visit (15+ min) | 41 | $2,166 | $53 |
| Return visit (30+ min) | 27 | $2,152 | $74 |
| Destruction of precancer skin growth, 1 growth | 39 | $1,997 | $39 |
| Destruction of skin growth, 1-14 growths | 18 | $1,650 | $75 |
| Destruction of precancer skin growth, 2-14 growths | 25 | $579 | $4 |
2015: 8 services
| New patient visit (30+ min) | 60 | $4,336 | $72 |
| Return visit (30+ min) | 39 | $3,548 | $75 |
| Biopsy of single growth of skin and/or tissue | 42 | $3,418 | $73 |
| Short return visit (20+ min) | 49 | $3,353 | $51 |
| Destruction of precancer skin growth, 1 growth | 43 | $2,407 | $43 |
| Destruction of precancer skin growth, 15 or more growths | 12 | $1,433 | $119 |
| New patient visit (15+ min) | 22 | $811 | $37 |
| Destruction of precancer skin growth, 2-14 growths | 28 | $623 | $4 |
2014: 7 services
| Biopsy of single growth of skin and/or tissue | 51 | $3,974 | $75 |
| New patient visit (30+ min) | 49 | $3,687 | $75 |
| Short return visit (20+ min) | 54 | $3,624 | $52 |
| Return visit (30+ min) | 38 | $3,288 | $75 |
| Destruction of precancer skin growth, 1 growth | 41 | $1,991 | $41 |
| Destruction of precancer skin growth, 2-14 growths | 31 | $1,375 | $8 |
| New patient visit (15+ min) | 22 | $1,058 | $48 |
2013: 7 services
| Short return visit (20+ min) | 55 | $3,180 | $48 |
| Return visit (30+ min) | 35 | $2,699 | $69 |
| Biopsy of single growth of skin and/or tissue | 28 | $2,223 | $77 |
| New patient visit (30+ min) | 30 | $2,165 | $72 |
| Destruction of precancer skin growth, 1 growth | 33 | $2,129 | $52 |
| New patient visit (15+ min) | 37 | $1,803 | $49 |
| Destruction of precancer skin growth, 2-14 growths | 21 | $569 | $5 |
Medicaid work
$36,546 in 2024
Medicaid paid $36,546 for 834 billed services this clinician did in 2024, up to 40 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 345 | $12,689 |
| Return visit (30+ min) | 225 | $10,525 |
| New patient visit (30+ min) | 170 | $10,078 |
| Short return visit | 55 | $1,182 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 26 | $1,049 |
| Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion | 13 | $1,023 |
| 2024 | 834 | 6 | 40 | $36,546 |
| 2023 | 1,061 | 6 | 60 | $46,869 |
| 2022 | 1,088 | 7 | 52 | $52,045 |
| 2021 | 804 | 6 | 33 | $38,410 |
| 2020 | 122 | 3 | 27 | $4,570 |
See the largest Medicaid services in earlier years
2023
| Short return visit (20+ min) | 474 | $17,115 |
| Return visit (30+ min) | 322 | $16,680 |
| New patient visit (30+ min) | 150 | $8,959 |
| Short return visit | 77 | $1,682 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 18 | $1,565 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 20 | $868 |
2022
| New patient visit (30+ min) | 296 | $17,148 |
| Short return visit (20+ min) | 406 | $14,503 |
| Return visit (30+ min) | 280 | $14,392 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 46 | $3,623 |
| New patient visit (45+ min) | 12 | $986 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 15 | $705 |
| Short return visit | 33 | $688 |
2021
| Return visit (30+ min) | 299 | $15,702 |
| New patient visit (30+ min) | 167 | $9,735 |
| Short return visit (20+ min) | 259 | $9,215 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 46 | $1,989 |
| Destruction (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), of benign lesions other than skin tags or cutaneous vascular proliferative lesions; up to 14 lesions | 19 | $1,548 |
| Short return visit | 14 | $220 |
2020
| Short return visit (20+ min) | 62 | $1,806 |
| Return visit (30+ min) | 34 | $1,728 |
| OFFICE/OUTPATIENT NEW SF MDM 15 MINUTES | 26 | $1,036 |
Drugs they prescribed that Part D paid
$641,587
Pharmacies billed $641,587 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (16 of 865) in 2024. A higher opioid share than 9 in 10 peers; the typical dermatology clinician is at 0%.
771 generic and fewer than 11 brand-name prescriptions · $641,587 in drug cost · 152 antibiotic prescriptions to 50 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Bimzelx | 20 | $290,202 | $14,510 |
| Tacrolimus | 30 | $5,717 | $191 |
| Clobetasol Propionate | 121 | $4,085 | $34 |
| Doxycycline Monohydrate | 88 | $3,456 | $39 |
| Ketoconazole | 136 | $1,853 | $14 |
See all 15 drugs
| Bimzelx | 20 | $290,202 | $14,510 |
| Tacrolimus | 30 | $5,717 | $191 |
| Clobetasol Propionate | 121 | $4,085 | $34 |
| Doxycycline Monohydrate | 88 | $3,456 | $39 |
| Ketoconazole | 136 | $1,853 | $14 |
| Clindamycin Phosphate | 25 | $988 | $40 |
| Minocycline | 37 | $859 | $23 |
| Tretinoin | 20 | $614 | $31 |
| Doxycycline Hyclate | 25 | $473 | $19 |
| Triamcinolone Acetonide | 38 | $438 | $12 |
| Minoxidil | 52 | $315 | $6 |
| Nystatin | 21 | $207 | $10 |
| Terbinafine | 21 | $139 | $7 |
| Celecoxib | 11 | $110 | $10 |
| Prednisone | 35 | $97 | $3 |
Year by year
| 2024 | 865 | 207 | 2% (16) | None | $641,587 |
| 2023 | 750 | 216 | None | 11% | $752,797 |
| 2022 | 609 | 204 | None | 10% | $620,185 |
| 2021 | 412 | 147 | None | 12% | $263,928 |
| 2020 | 596 | 181 | None | 7% | $118,875 |
| 2019 | 648 | 216 | None | 12% | $197,660 |
| 2018 | 526 | 181 | None | 11% | $127,943 |
| 2017 | 410 | 147 | None | 9% | $81,739 |
| 2016 | 186 | 83 | None | 9% | $13,969 |
| 2015 | 180 | 79 | None | None | $15,069 |
| 2014 | 148 | 65 | None | 23% | $17,762 |
| 2013 | 121 | 59 | None | 24% | $13,193 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Skyrizi | 11 | $234,767 | $21,342 |
| Tremfya | 15 | $214,087 | $14,272 |
| Taltz | 14 | $109,415 | $7,815 |
| Cimzia | 12 | $87,006 | $7,251 |
| Clobetasol Propionate | 165 | $14,027 | $85 |
| Doxycycline Monohydrate | 81 | $3,716 | $46 |
| Ketoconazole | 101 | $2,020 | $20 |
| Clindamycin Phosphate | 27 | $1,028 | $38 |
| Tretinoin | 11 | $918 | $83 |
| Minocycline | 25 | $879 | $35 |
| Triamcinolone Acetonide | 59 | $679 | $12 |
| Terbinafine | 20 | $239 | $12 |
| Minoxidil | 28 | $235 | $8 |
| Prednisone | 42 | $223 | $5 |
| Nystatin | 16 | $219 | $14 |
2022: 13 drugs
| Tremfya | 19 | $251,393 | $13,231 |
| Tacrolimus | 19 | $7,879 | $415 |
| Clobetasol Propionate | 109 | $7,301 | $67 |
| Calcipotriene | 18 | $4,717 | $262 |
| Doxycycline Monohydrate | 60 | $2,169 | $36 |
| Ketoconazole | 101 | $1,838 | $18 |
| Minocycline | 23 | $1,375 | $60 |
| Clindamycin Phosphate | 14 | $838 | $60 |
| Triamcinolone Acetonide | 55 | $570 | $10 |
| Tretinoin | 11 | $428 | $39 |
| Metronidazole | 11 | $421 | $38 |
| Prednisone | 29 | $180 | $6 |
| Terbinafine | 11 | $151 | $14 |
2021: 8 drugs
| Tremfya | 11 | $135,984 | $12,362 |
| Clobetasol Propionate | 78 | $4,958 | $64 |
| Ketoconazole | 70 | $1,748 | $25 |
| Doxycycline Monohydrate | 41 | $1,380 | $34 |
| Ciclopirox | 12 | $959 | $80 |
| Triamcinolone Acetonide | 45 | $753 | $17 |
| Clindamycin Phosphate | 15 | $462 | $31 |
| Prednisone | 21 | $108 | $5 |
2020: 12 drugs
| Calcipotriene | 14 | $4,176 | $298 |
| Clobetasol Propionate | 57 | $2,670 | $47 |
| Ketoconazole | 103 | $2,248 | $22 |
| Doxycycline Monohydrate | 48 | $1,291 | $27 |
| Ciclopirox | 19 | $1,090 | $57 |
| Triamcinolone Acetonide | 97 | $1,041 | $11 |
| Minocycline | 18 | $763 | $42 |
| Clindamycin Phosphate | 18 | $479 | $27 |
| Nystatin | 17 | $262 | $15 |
| Prednisone | 39 | $247 | $6 |
| Spironolactone | 13 | $239 | $18 |
| Terbinafine | 14 | $125 | $9 |
2019: 12 drugs
| Stelara | 13 | $145,438 | $11,188 |
| Calcipotriene | 14 | $4,908 | $351 |
| Ketoconazole | 99 | $2,284 | $23 |
| Doxycycline Monohydrate | 81 | $2,128 | $26 |
| Fluocinonide | 21 | $1,462 | $70 |
| Clobetasol Propionate | 22 | $1,244 | $57 |
| Mometasone Furoate | 47 | $1,191 | $25 |
| Ciclopirox | 15 | $1,113 | $74 |
| Triamcinolone Acetonide | 111 | $940 | $8 |
| Minocycline | 16 | $927 | $58 |
| Prednisone | 54 | $341 | $6 |
| Terbinafine | 14 | $140 | $10 |
2018: 11 drugs
| Calcipotriene | 11 | $4,271 | $388 |
| Clobetasol Propionate | 38 | $2,994 | $79 |
| Fluocinonide | 14 | $2,718 | $194 |
| Doxycycline Monohydrate | 52 | $1,635 | $31 |
| Ketoconazole | 70 | $1,412 | $20 |
| Triamcinolone Acetonide | 106 | $1,109 | $10 |
| Betamethasone Valerate | 17 | $738 | $43 |
| Minocycline | 11 | $437 | $40 |
| Prednisone | 57 | $353 | $6 |
| Spironolactone | 15 | $230 | $15 |
| Terbinafine | 12 | $122 | $10 |
2017: 8 drugs
| Calcipotriene | 19 | $4,474 | $235 |
| Clobetasol Propionate | 31 | $3,080 | $99 |
| Doxycycline Hyclate | 41 | $1,511 | $37 |
| Triamcinolone Acetonide | 93 | $1,496 | $16 |
| Doxycycline Monohydrate | 28 | $1,172 | $42 |
| Ketoconazole | 38 | $1,124 | $30 |
| Tretinoin | 11 | $525 | $48 |
| Prednisone | 34 | $263 | $8 |
2016: 5 drugs
| Clobetasol Propionate | 24 | $3,723 | $155 |
| Doxycycline Hyclate | 24 | $1,031 | $43 |
| Ketoconazole | 33 | $1,012 | $31 |
| Triamcinolone Acetonide | 17 | $137 | $8 |
| Prednisone | 14 | $95 | $7 |
2015: 4 drugs
| Clobetasol Propionate | 35 | $7,288 | $208 |
| Doxycycline Hyclate | 28 | $2,118 | $76 |
| Ketoconazole | 30 | $1,070 | $36 |
| Sulfamethoxazole-Trimethoprim | 12 | $94 | $8 |
2014: 4 drugs
| Doxycycline Hyclate | 22 | $2,599 | $118 |
| Clobetasol Propionate | 14 | $1,255 | $90 |
| Tretinoin | 11 | $846 | $77 |
| Ketoconazole | 14 | $189 | $14 |
2013: 1 drug
| Doxycycline Hyclate | 14 | $3,203 | $229 |
Money from drug and device companies
$42,961 in 2025
| 2025 | 21 | 120 | $37,450 | $42,961 |
| 2024 | 18 | 266 | $31,277 | $36,815 |
| 2023 | 18 | 287 | $21,365 | $29,806 |
| 2022 | 21 | 210 | $14,855 | $18,559 |
| 2021 | 16 | 135 | $9,450 | $11,742 |
| 2020 | 11 | 75 | $7,775 | $8,900 |
| 2019 | 10 | 135 | $31,250 | $33,872 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Biotech | Tremfya | $40,949 | 39 payments
|
| Galderma Laboratories L.P. | Nemluvio | $449 | 24 payments
|
| Abbvie | Skyrizi | $195 | 10 payments
|
| Stryker | Pangea | $169 | 1 payment
|
| Incyte | Opzelura | $146 | 6 payments
|
| Genzyme | Dupixent | $128 | 3 payments
|
See all 120 published payments
| Lnhc | Meals · 2025-12-24 | Zelsuvmi | $24 |
| Amgen | Meals · 2025-12-15 | Otezla | $28 |
| Galderma Laboratories L.P. | Meals · 2025-12-13 | Aklief | $7 |
| Ucb | Meals · 2025-12-12 | Bimzelx | $32 |
| Incyte | Meals · 2025-12-09 | Opzelura | $21 |
| Galderma Laboratories L.P. | Meals · 2025-12-01 | Nemluvio | $9 |
| Abbvie | Meals · 2025-11-21 | Skyrizi | $28 |
| Incyte | Meals · 2025-11-20 | Opzelura | $25 |
| Janssen Biotech | Meals · 2025-11-19 | Tremfya | $6 |
| Sun Pharmaceutical Industries | Meals · 2025-11-18 | Ilumya | $29 |
| Arcutis Biotherapeutics | Meals · 2025-11-14 | Zoryve | $21 |
| Novartis Pharmaceuticals | Meals · 2025-11-12 | Rhapsido | $29 |
| Janssen Biotech | Meals · 2025-11-08 | Tremfya | $7 |
| Ucb | Meals · 2025-11-07 | Bimzelx | $34 |
| Incyte | Meals · 2025-11-07 | Opzelura | $27 |
| Galderma Laboratories L.P. | Meals · 2025-11-04 | Nemluvio | $150 |
| Galderma Laboratories L.P. | Meals · 2025-10-29 | Nemluvio | $15 |
| Janssen Biotech | Paid to speak or teach · 2025-10-25 | Tremfya | $3,150 |
| Janssen Biotech | Meals · 2025-10-22 | Tremfya | $100 |
| Abbvie | Meals · 2025-10-17 | Skyrizi | $8 |
| Incyte | Meals · 2025-10-14 | Opzelura | $21 |
| Amgen | Meals · 2025-10-13 | Otezla | $22 |
| Janssen Biotech | Paid to speak or teach · 2025-10-11 | Tremfya | $1,400 |
| Janssen Biotech | Paid to speak or teach · 2025-10-11 | Tremfya | $3,150 |
| Galderma Laboratories L.P. | Meals · 2025-10-08 | Nemluvio | $4 |
| Janssen Biotech | Meals · 2025-10-07 | Tremfya | $125 |
| Almirall | Meals · 2025-10-02 | Seysara | $24 |
| Galderma Laboratories L.P. | Meals · 2025-10-01 | Nemluvio | $5 |
| Galderma Laboratories L.P. | Meals · 2025-10-01 | Nemluvio | $2 |
| Novartis Pharmaceuticals | Meals · 2025-09-30 | Cosentyx | $31 |
| Janssen Biotech | Paid to speak or teach · 2025-09-27 | Tremfya | $4,900 |
| Janssen Biotech | Meals · 2025-09-26 | Tremfya | $18 |
| Regeneron Healthcare Solutions | Meals · 2025-09-26 | Dupixent | $29 |
| Janssen Biotech | Travel · 2025-09-25 | Tremfya | $912 |
| Janssen Biotech | Meals · 2025-09-25 | Tremfya | $124 |
| Sun Pharmaceutical Industries | Meals · 2025-09-23 | Ilumya | $26 |
| Janssen Biotech | Meals · 2025-09-17 | Tremfya | $29 |
| Galderma Laboratories L.P. | Meals · 2025-09-17 | Nemluvio | $8 |
| LEO Pharma | Meals · 2025-09-15 | Anzupgo | $27 |
| Verrica Pharmaceuticals | Meals · 2025-09-11 | Ycanth | $20 |
| Ucb | Meals · 2025-09-11 | Bimzelx | $28 |
| Galderma Laboratories L.P. | Meals · 2025-09-11 | Nemluvio | $7 |
| Galderma Laboratories L.P. | Meals · 2025-09-10 | Nemluvio | $8 |
| Incyte | Meals · 2025-09-09 | Opzelura | $26 |
| Galderma Laboratories L.P. | Meals · 2025-08-29 | Aklief | $7 |
| Janssen Biotech | Meals · 2025-08-26 | Tremfya | $29 |
| Amgen | Meals · 2025-08-13 | Otezla | $30 |
| Regeneron Healthcare Solutions | Meals · 2025-08-12 | Dupixent | $34 |
| Arcutis Biotherapeutics | Meals · 2025-08-10 | Zoryve | $19 |
| Galderma Laboratories L.P. | Meals · 2025-08-06 | Nemluvio | $6 |
| Galderma Laboratories L.P. | Meals · 2025-08-06 | Nemluvio | $150 |
| Abbvie | Meals · 2025-08-05 | Skyrizi | $8 |
| Amgen | Meals · 2025-07-29 | Otezla | $23 |
| Almirall | Meals · 2025-07-28 | Seysara | $16 |
| Janssen Biotech | Paid to speak or teach · 2025-07-26 | Tremfya | $1,050 |
| Janssen Biotech | Meals · 2025-07-18 | Tremfya | $9 |
| Galderma Laboratories L.P. | Meals · 2025-07-16 | Aklief | $6 |
| Incyte | Meals · 2025-07-15 | Opzelura | $27 |
| LEO Pharma | Meals · 2025-07-14 | Adbry | $22 |
| Paratek Pharmaceuticals | Meals · 2025-07-10 | Nuzyra | $21 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-10 | Spevigo | $27 |
| Galderma Laboratories L.P. | Meals · 2025-07-08 | Nemluvio | $4 |
| Arcutis Biotherapeutics | Meals · 2025-07-06 | Zoryve | $18 |
| Helsinn Therapeutics (U.S.) | Meals · 2025-07-02 | Valchlor | $18 |
| Janssen Biotech | Travel · 2025-07-01 | Tremfya | $55 |
| Janssen Biotech | Travel · 2025-07-01 | Tremfya | $6 |
| Abbvie | Meals · 2025-06-27 | Skyrizi | $17 |
| Janssen Biotech | Paid to speak or teach · 2025-06-26 | Tremfya | $3,150 |
| Janssen Biotech | Meals · 2025-06-26 | Tremfya | $25 |
| Galderma Laboratories L.P. | Meals · 2025-06-25 | Nemluvio | $5 |
| Galderma Laboratories L.P. | Meals · 2025-06-25 | Nemluvio | $2 |
| Abbvie | Meals · 2025-06-23 | Skyrizi | $24 |
| Janssen Biotech | Paid to speak or teach · 2025-06-21 | Tremfya | $4,900 |
| Janssen Biotech | Meals · 2025-06-19 | Tremfya | $123 |
| Janssen Biotech | Travel · 2025-06-19 | Tremfya | $211 |
| Janssen Biotech | Travel · 2025-06-19 | Tremfya | $147 |
| Janssen Biotech | Meals · 2025-06-18 | Tremfya | $5 |
| Sun Pharmaceutical Industries | Meals · 2025-06-15 | Ilumya | $28 |
| Janssen Biotech | Paid to speak or teach · 2025-06-06 | Tremfya | $10 |
| Janssen Biotech | Meals · 2025-06-04 | Tremfya | $6 |
| Novartis Pharmaceuticals | Meals · 2025-06-03 | Cosentyx | $31 |
| Galderma Laboratories L.P. | Meals · 2025-06-03 | Nemluvio | $5 |
| Galderma Laboratories L.P. | Meals · 2025-05-29 | Nemluvio | $6 |
| Regeneron Healthcare Solutions | Meals · 2025-05-28 | Dupixent | $33 |
| Janssen Biotech | Paid to speak or teach · 2025-05-24 | Tremfya | $3,150 |
| Janssen Biotech | Meals · 2025-05-21 | Tremfya | $146 |
| Amgen | Meals · 2025-05-19 | Otezla | $22 |
| Janssen Biotech | Travel · 2025-05-16 | Tremfya | $42 |
| Galderma Laboratories L.P. | Meals · 2025-05-15 | Nemluvio | $5 |
| Genzyme | Meals · 2025-05-14 | Dupixent | $50 |
| Janssen Biotech | Paid to speak or teach · 2025-05-10 | Tremfya | $3,150 |
| Janssen Biotech | Meals · 2025-05-07 | Tremfya | $150 |
| Janssen Biotech | Paid to speak or teach · 2025-05-03 | Tremfya | $4,900 |
| Janssen Biotech | Meals · 2025-04-30 | Tremfya | $119 |
| Janssen Biotech | Travel · 2025-04-30 | Tremfya | $951 |
| Abbvie | Meals · 2025-04-30 | Skyrizi | $23 |
| Regeneron Healthcare Solutions | Meals · 2025-04-24 | Dupixent | $25 |
| Janssen Biotech | Meals · 2025-04-22 | Tremfya | $24 |
| Sun Pharmaceutical Industries | Meals · 2025-04-21 | Ilumya | $43 |
| Botanix SB | Meals · 2025-04-16 | Sofdra | $23 |
| Arcutis Biotherapeutics | Meals · 2025-04-13 | Zoryve | $18 |
| Stryker | Meals · 2025-03-29 | Pangea | $169 |
| Abbvie | Meals · 2025-03-28 | Skyrizi | $33 |
| Abbvie | Education · 2025-03-28 | Skyrizi | $10 |
| LEO Pharma | Meals · 2025-03-26 | Adbry | $17 |
| Galderma Laboratories L.P. | Meals · 2025-03-24 | Aklief | $9 |
| Galderma Laboratories L.P. | Meals · 2025-03-24 | Aklief | $3 |
| Janssen Biotech | Paid to speak or teach · 2025-03-22 | Tremfya | $3,150 |
| Janssen Biotech | Paid to speak or teach · 2025-03-22 | Tremfya | $1,390 |
| Galderma Laboratories L.P. | Meals · 2025-03-21 | Nemluvio | $13 |
| Janssen Biotech | Meals · 2025-03-19 | Tremfya | $100 |
| Janssen Biotech | Meals · 2025-03-19 | Tremfya | $29 |
| Arcutis Biotherapeutics | Meals · 2025-03-14 | Zoryve | $23 |
| Paratek Pharmaceuticals | Meals · 2025-03-12 | Nuzyra | $21 |
| Mayne Pharma Commercial | Meals · 2025-02-28 | None | $8 |
| Genzyme | Meals · 2025-02-25 | Dupixent | $40 |
| Abbvie | Meals · 2025-02-19 | Skyrizi | $28 |
| Genzyme | Meals · 2025-02-13 | Dupixent | $39 |
| Galderma Laboratories L.P. | Meals · 2025-02-10 | Nemluvio | $14 |
| Abbvie | Meals · 2025-02-05 | Skyrizi | $16 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $36,815
| Janssen Biotech | Tremfya | $33,785 | 68 payments
|
| Abbvie | Skyrizi | $451 | 34 payments
|
| Incyte | Opzelura | $325 | 19 payments
|
| Ucb | Bimzelx | $323 | 13 payments
|
| Amgen | Otezla | $303 | 16 payments
|
| Lilly USA | Taltz | $268 | 20 payments
|
| Mayne Pharma Commercial | None | $245 | 26 payments
|
| Novartis Pharmaceuticals | Cosentyx | $224 | 9 payments
|
| Arcutis Biotherapeutics | Zoryve | $203 | 16 payments
|
| Pfizer | Eucrisa | $200 | 14 payments
|
| Ortho Dermatologics a division of Bausch Health US | Cabtreo | $141 | 10 payments
|
| Galderma Laboratories L.P. | Aklief | $134 | 10 payments
|
| Regeneron Healthcare Solutions | Dupixent | $59 | 2 payments
|
| Paratek Pharmaceuticals | Nuzyra | $45 | 3 payments
|
| Sun Pharmaceutical Industries | Winlevi | $36 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $35 | 2 payments
|
| LEO Pharma | Adbry | $24 | 1 payment
|
| Revance Therapeutics | Daxxify | $14 | 1 payment
|
2023: $29,806
| Incyte | Opzelura | $18,330 | 42 payments
|
| Janssen Biotech | Tremfya | $8,544 | 61 payments
|
| Ucb | Cimzia | $570 | 26 payments
|
| Lilly USA | Taltz | $284 | 14 payments
|
| AbbVie | Skyrizi | $278 | 22 payments
|
| Novartis Pharmaceuticals | Cosentyx | $261 | 10 payments
|
| Amgen | Otezla | $213 | 11 payments
|
| Mayne Pharma Commercial | None | $202 | 26 payments
|
| Regeneron Healthcare Solutions | Dupixent | $187 | 6 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $155 | 13 payments
|
| Arcutis Biotherapeutics | None | $153 | 12 payments
|
| Pfizer | Eucrisa | $153 | 13 payments
|
| Sun Pharmaceutical Industries | Ilumya | $143 | 8 payments
|
| Galderma Laboratories L.P. | Twyneo | $134 | 12 payments
|
| LEO Pharma | Adbry | $62 | 3 payments
|
| Almirall | Seysara | $51 | 3 payments
|
| Ortho Dermatologics a division of Bausch Health US | Jublia | $46 | 3 payments
|
| Genzyme | Dupixent | $40 | 2 payments
|
2022: $18,559
| Incyte | Opzelura | $15,694 | 33 payments
|
| Janssen Biotech | Tremfya | $511 | 32 payments
|
| Abbvie | Skyrizi | $416 | 29 payments
|
| Mayne Pharma | None | $289 | 32 payments
|
| Amgen | Otezla | $246 | 13 payments
|
| Novartis Pharmaceuticals | Cosentyx | $196 | 9 payments
|
| Regeneron Healthcare Solutions | Dupixent | $188 | 6 payments
|
| Sun Pharmaceutical Industries | Ilumya | $178 | 9 payments
|
| Ortho Dermatologics a division of Bausch Health US | Arazlo | $162 | 11 payments
|
| Pfizer | Cibinqo | $135 | 8 payments
|
| Lilly USA | Taltz | $127 | 6 payments
|
| Galderma Laboratories L.P. | Oracea | $85 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Sotyktu | $67 | 3 payments
|
| LEO Pharma | Adbry | $64 | 3 payments
|
| Allergan | Botox | $55 | 3 payments
|
| Ucb | Cimzia | $54 | 2 payments
|
| Almirall | Seysara | $41 | 3 payments
|
| EPI Health | Cloderm | $16 | 1 payment
|
| Nabriva Therapeutics plc | Sivextro | $14 | 1 payment
|
| Medimetriks Pharmaceuticals | Clindacin Etz | $12 | 1 payment
|
| Kerecis | Kerecis Omega3 Surgiclose | $7 | 1 payment
|
2021: $11,742
| Incyte | Opzelura | $6,443 | 9 payments
|
| Pfizer | Eucrisa | $3,680 | 14 payments
|
| AbbVie | Skyrizi | $340 | 24 payments
|
| Janssen Biotech | Tremfya | $239 | 12 payments
|
| Mayne Pharma | None | $228 | 19 payments
|
| Ortho Dermatologics a division of Bausch Health US | Arazlo | $210 | 23 payments
|
| Amgen | Otezla | $191 | 12 payments
|
| Lilly USA | Taltz | $87 | 3 payments
|
| Novartis Pharmaceuticals | Cosentyx | $63 | 3 payments
|
| Sun Pharmaceutical Industries | Ilumya | $59 | 3 payments
|
| Galderma Laboratories L.P. | Aklief | $52 | 4 payments
|
| LEO Pharma | Enstilar | $52 | 3 payments
|
| Allergan | Botox | $36 | 2 payments
|
| Nabriva Therapeutics plc | Sivextro | $33 | 2 payments
|
| Merz North America | Xeomin | $18 | 1 payment
|
| VYNE Pharmaceuticals | Amzeeq | $11 | 1 payment
|
2020: $8,900
| Pfizer | Eucrisa | $7,848 | 9 payments
|
| Mayne Pharma | Doryx | $604 | 41 payments
|
| Janssen Biotech | Tremfya | $154 | 4 payments
|
| Galderma Laboratories L.P. | Epiduo Forte | $130 | 13 payments
|
| LEO Pharma | Enstilar | $41 | 2 payments
|
| Merz North America | Xeomin | $25 | 1 payment
|
| Sun Pharmaceutical Industries | Ilumya | $25 | 1 payment
|
| Dermira | Qbrexza | $24 | 1 payment
|
| AbbVie | Skyrizi | $20 | 1 payment
|
| Amgen | Otezla | $16 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Arazlo | $12 | 1 payment
|
2019: $33,872
| Pfizer | Eucrisa | $32,785 | 37 payments
|
| Mayne Pharma | Doryx | $671 | 61 payments
|
| Galderma Laboratories L.P. | Epiduo Forte | $137 | 20 payments
|
| LEO Pharma | Enstilar | $81 | 5 payments
|
| AbbVie | Skyrizi | $54 | 2 payments
|
| Merck Sharp & Dohme | Sivextro | $50 | 4 payments
|
| Merz North America | Xeomin | $37 | 2 payments
|
| Mylan Pharmaceuticals | Olux | $24 | 2 payments
|
| Sun Pharmaceutical Industries | Ilumya | $21 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Siliq | $12 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Amgen Inc. · Abp 654 P3 Pso Study · 2021 | Their institution | $233,154 |
| AbbVie, Inc. · Skyrizi · 2019 | Their institution | $97,545 |
| GlaxoSmithKline, LLC. · A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controll · 2022 | Their institution | $94,227 |
| AbbVie Inc. · Skyrizi · 2020 | Their institution | $54,945 |
| Amgen Inc. · Abp 654 P3 Pso Study · 2022 | Their institution | $53,022 |
| Endo Pharmaceuticals Inc. · A Phase 3b, Open-Label, Long-Term Study To Evaluate the Safety and Temporal Pattern of Response of En3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy · 2019 | Their institution | $41,230 |
| PFIZER INC. · A Phase 3b Randomized Doubleblind Doubledummy Active Controlled Multicenter Study Assessing the Efficacy and Safety of Abrocitinib Compared With Dupilumab in Adult Participants on Background Topical Therapy With Moderate To Severe Atopic Dermatitis · 2021 | Their institution | $40,905 |
| Mindera Corp · Match Study · 2023 | Their institution | $37,898 |
| Amgen Inc. · Ph3 Otezla in Peds Mild/Mod Pso Pmr · 2024 | Their institution | $33,111 |
| SUN PHARMACEUTICAL INDUSTRIES INC. · A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Scd-044 in the Treatment of Moderate To Severe Plaque Psoriasis · 2024 | Their institution | $32,332 |
| E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study To Evaluate the Clinical Efficacy and Safety of Bms-986165 in Subjects With Moderate To Severe Psoriasis · 2019 | Their institution | $30,468 |
| PFIZER INC. · A Phase 3b Randomized Doubleblind Doubledummy Active Controlled Multicenter Study Assessing the Efficacy and Safety of Abrocitinib Compared With Dupilumab in Adult Participants on Background Topical Therapy With Moderate To Severe Atopic Dermatitis · 2020 | Their institution | $24,585 |
| Janssen Research & Development, LLC · Cnto1959pso3017 · 2024 | Their institution | $23,405 |
| SANOFI US SERVICES INC. · A Randomized, Double Blind, Placebo-Controlled, Multi-Center, Parallel Group Study To Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies Or When Those Therapies Are Not Advisable · 2021 | Their institution | $22,865 |
| E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study To Evaluate the Clinical Efficacy and Safety of Bms-986165 in Subjects With Moderate To Severe Psoriasis · 2020 | Their institution | $22,729 |
| SUN PHARMACEUTICAL INDUSTRIES INC. · A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Scd-044 in the Treatment of Moderate To Severe Atopic Dermatitis · 2024 | Their institution | $21,804 |
| GlaxoSmithKline, LLC. · A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controll · 2023 | Their institution | $20,311 |
| PFIZER INC. · A Phase 2b Randomized Doubleblind 12week Placebocontrolled Study With A 12week Doubleblind Extension Period To Evaluate the Efficacy Safety and Tolerability of Ritlecitinib Pf06651600 in Adult Participants With Chronic Spontaneous Urticaria · 2025 | Their institution | $18,850 |
| PFIZER INC. · A Phase 23 Twopart Study To Evaluate the Efficacy and Longterm Safety With Oral Etrasimod 2 Mg Once Daily in Adult Participants With Moderatetosevere Atopic Dermatitis With A History of Prior Systemic Treatment Failure · 2023 | Their institution | $17,563 |
| Amgen Inc. · Ph3 Otezla in Peds Mild/Mod Pso (Pmr) · 2023 | Their institution | $16,830 |
| E.R. Squibb & Sons, L.L.C. · Long-Term Study That Measures the Safety and Efficacy of Bms-986165 in Participants With Psoriasis · 2020 | Their institution | $14,935 |
| ABBVIE INC. · A Study of Upadacitinib in Adult Participants With Moderate-To-Severe Atopic Dermatitis and Inadequate Response To Dupilumab (Switch-Up) · 2024 | Their institution | $13,535 |
| Dermavant Sciences, Inc. · An Open Label, Long-Term Extension Study To Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis · 2024 | Their institution | $13,155 |
| PFIZER INC. · An Openlabel Extension Study To Assess the Longterm Safety and Efficacy of Pf04965842 in Adult Patients With Moderatetosevere Atopic Dermatitis · 2020 | Their institution | $13,090 |
| Taro Pharmaceuticals USA, Inc. · A Randomized, Double-Blind, Placebo-Controlled Study To Assess the Efficacy and Safety of Scd-044 in the Treatment of Moderate To Severe Atopic Dermatitis · 2023 | Their institution | $12,000 |
| Amgen Inc. · Abp 654 Phase 3 Pso Study · 2020 | Their institution | $11,167 |
| Amgen Inc. · Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate To Severe Hidradenitis Suppurativa · 2022 | Their institution | $8,750 |
| E.R. Squibb & Sons, L.L.C. · Long-Term Study That Measures the Safety and Efficacy of Bms-986165 in Participants With Psoriasis · 2023 | Their institution | $7,799 |
| ABBVIE INC. · A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study To Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate To Severe Atopic Dermatitis · 2021 | Their institution | $7,047 |
| SANOFI US SERVICES INC. · A Randomized, Double Blind, Placebo-Controlled, Multi-Center, Parallel Group Study To Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies Or When Those Therapies Are Not Advisable · 2020 | Their institution | $6,791 |
| Dermavant Sciences, Inc. · A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Moderate To Severe Atopic Dermatitis in Children With Adults · 2023 | Their institution | $6,732 |
| E.R. Squibb & Sons, L.L.C. · Long-Term Study That Measures the Safety and Efficacy of Bms-986165 in Participants With Psoriasis · 2021 | Their institution | $6,599 |
| PFIZER INC. · A Phase 23 Twopart Study To Evaluate the Efficacy and Longterm Safety With Oral Etrasimod 2 Mg Once Daily in Adult Participants With Moderatetosevere Atopic Dermatitis With A History of Prior Systemic Treatment Failure · 2024 | Their institution | $6,150 |
| Dermavant Sciences, Inc. · An Open Label, Long-Term Extension Study To Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis · 2022 | Their institution | $6,023 |
| Amgen Inc. · Abp 654 P3 Pso Study · 2024 | Their institution | $6,000 |
| SANOFI US SERVICES INC. · A Randomized, Double Blind, Placebo-Controlled, Multi-Center, Parallel Group Study To Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies Or When Those Therapies Are Not Advisable · 2022 | Their institution | $5,000 |
| SANOFI US SERVICES INC. · Master Protocol of Two Randomized, Double-Blind, Placebo Controlled, Multi-Center, Parallel-Group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (Csu) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients Naive To Omalizumab and in Patients Who Are Intolerant Or Incomplete Responders To Omalizumab · 2023 | Their institution | $4,950 |
| SANOFI US SERVICES INC. · Master Protocol of Two Randomized, Double-Blind, Placebo Controlled, Multi-Center, Parallel-Group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (Csu) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients Naive To Omalizumab and in Patients Who Are Intolerant Or Incomplete Responders To Omalizumab · 2021 | Their institution | $4,000 |
| Endo Pharmaceuticals Inc. · A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of En3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy Cellulite · 2019 | Their institution | $3,750 |
| E.R. Squibb & Sons, L.L.C. · A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study To Evaluate the Clinical Efficacy and Safety of Bms-986165 in Subjects With Moderate To Severe Psoriasis · 2021 | Their institution | $2,558 |
| UCB SA · A Phase 3, Multicenter, Double-Blind, Placebo Controlled Study With An Initial Treatment Period Followed By A Randomized-Withdrawal Period To Evaluate the Efficacy and Safety of Bimekizumab in Adult S · 2020 | Their institution | $2,500 |
| UCB SA · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study To Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate To · 2020 | Their institution | $2,500 |
| ABBVIE INC. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess the Safety and Efficacy of Risankizumab Using A New Formulation for the Treatment of Adult Subjects With Moderate To Severe Plaque Psoriasis · 2021 | Their institution | $2,475 |
| E.R. Squibb & Sons, L.L.C. · Long-Term Study That Measures the Safety and Efficacy of Bms-986165 in Participants With Psoriasis · 2022 | Their institution | $1,750 |
| UCB SA · A Phase 3, Multicenter, Double-Blind, Placebo Controlled Study With An Initial Treatment Period Followed By A Randomized-Withdrawal Period To Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate To Severe Chronic Plaque Psoriasis. · 2019 | Their institution | $1,400 |
| UCB SA · A Phase 3 Multicenter, Randomized, Double-Blind, Placebo - and Active Comparator-Controlled, Parallel Group Study To Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate To Severe Chronic Plaque Psoriasis · 2019 | Their institution | $1,400 |
| Dermavant Sciences, Inc. · An Open Label, Long-Term Extension Study To Evaluate the Safety and Efficacy of Tapinarof Cream 1% in Subjects With Atopic Dermatitis · 2023 | Their institution | $1,010 |
| Eli Lilly and Company · A Long-Term Study To Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis · 2023 | Their institution | $550 |
| ABBVIE INC. · A Study To Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate To Severe Atopic Dermatitis · 2022 | Their institution | $263 |
Professional record
- NPI
- 1821165143
- Licence
- GA 056951, TX N9338Texas N9338: Active
- Trained
- University of Chicago, Pritzker School of Medicine, 1999 · 27 years ago
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- GA 179353931
- Taxonomy
- Federal specialty code 207N00000X (207N00000X); Federal specialty code 207NS0135X (207NS0135X)
- Mailing address
- 7345 Medical Center Dr Ste 310, West Hills, CA, 91307
- NPI first listed
- 2006-11-30
- NPI last updated
- 2025-02-25
- NPI record certified
- 2025-02-25
This is when the NPI record was last certified, not a medical board exam.